Bristol-Myers Squibb Makes Case For Success Of Opdivo With Latest Long-Term Kidney Cancer Data [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
Summary Bristol-Myers Squibb obtains positive long-term data in two separate studies treating patients with advanced kidney cancer. One study used Opdivo in advanced RCC patients who received prior anti angiogenic therapy such as everolimus, while the other study explored Opdivo and Yervoy in first line patients. Full-year 2019 sales of Opdivo grew by 7% year over year to $7.2 billion. Completed acquisition of Celgene, which added additional oncology drugs to Bristol-Myers Squibb's pipeline such as: Revlimid, Abraxane and Pomalyst. BMY announced that it had received positive results Merck MRK Positive Long-Term Data Makes Case For Opdivo To Treat Kidney Cancer The first phase 3 study, known as CheckMate-214, was an open-label study. This study looked at previously untreated advanced or metastatic renal cell carcinoma (RCC). Patients in one dosing group received Opdivo plus Yervoy in this first-line advanced RCC population. The other dosing group had only received standard of care (SOC
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L TrialBusiness Wire
- EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member [Yahoo! Finance]Yahoo! Finance
- 2 Beaten-Down Stocks to Buy and Hold for 10 Years [Yahoo! Finance]Yahoo! Finance
- 2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 5/9/24 - Form 8-K
- 5/3/24 - Form 4
- 4/25/24 - Form 10-Q
- BMY's page on the SEC website